LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY.

The R&D day will feature presentations by internal ProQR and external speakers on the progress of the ophthalmology pipeline, including an update on the progress of sepofarsen (formerly named QR-110) for LCA10 and QR-421a for Usher syndrome and discussion of the next therapies to enter the clinic. Speakers will discuss state of the art in research relevant to current and upcoming areas of the company’s pipeline, including the role oligonucleotide therapies will play in accelerating the translation of molecular insights into approved therapies for areas of high unmet medical need.

R&D Day Event Details

The event will be held on Tuesday, January 29, 2019 at the Lotte New York Palace Hotel in New York City. Doors will open at 7:30 am and will end around noon.  Registration for the event can be found at ProQR R&D Day Registration.

Webcast

The live and archived webcast of the presentation will be accessible from the Investor Relations section of ProQR’s website (www.proqr.com) under Events and Presentations. The archived webcast will be available for 90 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, Usher syndrome type 2 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions, including statements regarding the progress of our development and plans for our product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.
Investor Contact:
Lisa Hayes
Vice President of Investor Relations and Corporate Communications
T: +1 202 360 4855
ir@proqr.com

Media Contact:
Sara Zelkovic
LifeSci Public Relations
T: +1 646 876 4933
Sara@lifescipublicrelations.com